Emerging vaccines for influenza

Pritish K. Tosh, Gregory A. Poland

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Influenza remains one of the leading causes of morbidity and mortality worldwide. The available vaccines are least effective in the populations at greatest risk - children, the elderly, and the immunocompromised. Furthermore, avian influenza and other novel strains have the potential to cause the next influenza pandemic. Research efforts have accelerated worldwide to develop new vaccines to provide better immunity against annual epidemics and a potential pandemic. Objective: To summarize the global research efforts at developing new influenza vaccines, adjuvants, and delivery devices. Method: MEDLINE and Pharmaprojects databases were searched for publications and continuing research on new influenza vaccine technologies. Results/conclusions: Technologies such as DNA vaccines, live recombinant viral vector vaccines, and virus-like particles have shown significant promise for immunogenicity and protection from experimental challenge to influenza. New modalities for vaccine delivery and methods for rapid vaccine production are also being investigated. With the possibility of an influenza pandemic increasing the need to develop new vaccines, the global research community has made large strides to meet this challenge.

Original languageEnglish (US)
Pages (from-to)21-40
Number of pages20
JournalExpert Opinion on Emerging Drugs
Volume13
Issue number1
DOIs
StatePublished - Mar 2008

Fingerprint

Influenza Vaccines
Vaccines
Human Influenza
Pandemics
Research
Viral Vaccines
Technology
Synthetic Vaccines
DNA Vaccines
Influenza in Birds
MEDLINE
Virion
Publications
Immunity
Databases
Morbidity
Equipment and Supplies
Mortality

Keywords

  • Influenza
  • Influenza vaccine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Emerging vaccines for influenza. / Tosh, Pritish K.; Poland, Gregory A.

In: Expert Opinion on Emerging Drugs, Vol. 13, No. 1, 03.2008, p. 21-40.

Research output: Contribution to journalArticle

Tosh, Pritish K. ; Poland, Gregory A. / Emerging vaccines for influenza. In: Expert Opinion on Emerging Drugs. 2008 ; Vol. 13, No. 1. pp. 21-40.
@article{ee9c0535535b47ac93e580b19e89671a,
title = "Emerging vaccines for influenza",
abstract = "Background: Influenza remains one of the leading causes of morbidity and mortality worldwide. The available vaccines are least effective in the populations at greatest risk - children, the elderly, and the immunocompromised. Furthermore, avian influenza and other novel strains have the potential to cause the next influenza pandemic. Research efforts have accelerated worldwide to develop new vaccines to provide better immunity against annual epidemics and a potential pandemic. Objective: To summarize the global research efforts at developing new influenza vaccines, adjuvants, and delivery devices. Method: MEDLINE and Pharmaprojects databases were searched for publications and continuing research on new influenza vaccine technologies. Results/conclusions: Technologies such as DNA vaccines, live recombinant viral vector vaccines, and virus-like particles have shown significant promise for immunogenicity and protection from experimental challenge to influenza. New modalities for vaccine delivery and methods for rapid vaccine production are also being investigated. With the possibility of an influenza pandemic increasing the need to develop new vaccines, the global research community has made large strides to meet this challenge.",
keywords = "Influenza, Influenza vaccine",
author = "Tosh, {Pritish K.} and Poland, {Gregory A.}",
year = "2008",
month = "3",
doi = "10.1517/14728214.13.1.21",
language = "English (US)",
volume = "13",
pages = "21--40",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging vaccines for influenza

AU - Tosh, Pritish K.

AU - Poland, Gregory A.

PY - 2008/3

Y1 - 2008/3

N2 - Background: Influenza remains one of the leading causes of morbidity and mortality worldwide. The available vaccines are least effective in the populations at greatest risk - children, the elderly, and the immunocompromised. Furthermore, avian influenza and other novel strains have the potential to cause the next influenza pandemic. Research efforts have accelerated worldwide to develop new vaccines to provide better immunity against annual epidemics and a potential pandemic. Objective: To summarize the global research efforts at developing new influenza vaccines, adjuvants, and delivery devices. Method: MEDLINE and Pharmaprojects databases were searched for publications and continuing research on new influenza vaccine technologies. Results/conclusions: Technologies such as DNA vaccines, live recombinant viral vector vaccines, and virus-like particles have shown significant promise for immunogenicity and protection from experimental challenge to influenza. New modalities for vaccine delivery and methods for rapid vaccine production are also being investigated. With the possibility of an influenza pandemic increasing the need to develop new vaccines, the global research community has made large strides to meet this challenge.

AB - Background: Influenza remains one of the leading causes of morbidity and mortality worldwide. The available vaccines are least effective in the populations at greatest risk - children, the elderly, and the immunocompromised. Furthermore, avian influenza and other novel strains have the potential to cause the next influenza pandemic. Research efforts have accelerated worldwide to develop new vaccines to provide better immunity against annual epidemics and a potential pandemic. Objective: To summarize the global research efforts at developing new influenza vaccines, adjuvants, and delivery devices. Method: MEDLINE and Pharmaprojects databases were searched for publications and continuing research on new influenza vaccine technologies. Results/conclusions: Technologies such as DNA vaccines, live recombinant viral vector vaccines, and virus-like particles have shown significant promise for immunogenicity and protection from experimental challenge to influenza. New modalities for vaccine delivery and methods for rapid vaccine production are also being investigated. With the possibility of an influenza pandemic increasing the need to develop new vaccines, the global research community has made large strides to meet this challenge.

KW - Influenza

KW - Influenza vaccine

UR - http://www.scopus.com/inward/record.url?scp=41549151683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549151683&partnerID=8YFLogxK

U2 - 10.1517/14728214.13.1.21

DO - 10.1517/14728214.13.1.21

M3 - Article

C2 - 18321146

AN - SCOPUS:41549151683

VL - 13

SP - 21

EP - 40

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -